MedPath

Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus

Phase 3
Completed
Conditions
Tetanus
Interventions
Drug: Human tetanus immunoglobulin (HTIG)
Registration Number
NCT05664750
Lead Sponsor
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Brief Summary

TNM002 Injection is a recombinant fully human native monoclonal antibody (mAb) against tetanus toxin and is currently under development for indication of prophylaxis against tetanus.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
675
Inclusion Criteria
  1. Chinese male or female adults aged ≥ 18 years;
  2. Participants with dirty or contaminated wounds caused by various injury who require passive immunization as prophylaxis against tetanus;
  3. Participants who provide signed written informed consent form.
Exclusion Criteria
  1. Known or suspected allergy to the investigational product or its excipients, or have a history of allergy to human immunoglobulin products or other therapeutic monoclonal immunoglobulins;
  2. Suspect or diagnosed as tetanus;
  3. Previously diagnosed as Immunoglobulin A (IgA) deficiency with anti-IgA antibodies
  4. Prior vaccination history of ≥ 3 doses of tetanus toxoid or tetanus toxoid- containing vaccine;
  5. Current alcohol abuse, drug abuse or drug addiction

Other protocol defined Inclusion/Exclusion criteria may apply

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TNM002TNM002If randomized to TNM002, participant will receive a single IM gluteal injection of TNM002
Human tetanus immunoglobulin (HTIG)Human tetanus immunoglobulin (HTIG)If randomized to HTIG, participant will receive a single IM gluteal injection of HTIG
Primary Outcome Measures
NameTimeMethod
Proportion of participants with an increase of anti-tetanus neutralizing antibody titers (∆ titers) over protective level.Baseline up to 12 hours after receipt of study drug
Secondary Outcome Measures
NameTimeMethod
Tetanus protection rate (1 - tetanus incidence)Up to 28 days after receipt of study drug

Trial Locations

Locations (28)

PKUCare Luzhong Hospital

🇨🇳

Zibo, Shandong, China

The Second Xiangya Hospital of Central South University

🇨🇳

Changsha, Hunan, China

Guangzhou First People's Hospital

🇨🇳

Guangzhou, Guangdong, China

Zhejiang Provincial People's Hospital

🇨🇳

Hangzhou, Hangzhou, China

The Central Hospital of Wuhan, Tongji Medical College Huazhong University of Science&Technology

🇨🇳

Wuhan, Hubei, China

Renmin Hospital of Wuhan University

🇨🇳

Wuhan, Hubei, China

General Hospital of Ningxia Medical University

🇨🇳

Yinchuan, Ningxia, China

Zhongnan Hospital of Wuhan University

🇨🇳

Wuhan, Hubei, China

Affiliated Nanhua Hospital, University of South China

🇨🇳

Hengyang, Hunan, China

The Second Affiliated Hospital of Nanchang University

🇨🇳

Nanchang, Jiangxi, China

The First People's Hospital of Jinzhong

🇨🇳

Jinzhong, Shanxi, China

Shanxi Academy of Medical Sciences - Shanxi Bethune Hospital (Shanxi Dayi Hospital)

🇨🇳

Taiyuan, Shanxi, China

Yuncheng Central Hospital - East Campus

🇨🇳

Yuncheng, Shanxi, China

Hefei First People's Hospital

🇨🇳

Hefei, Anhui, China

The Second Hospital of Anhui Medical University

🇨🇳

Hefei, Anhui, China

Peking University People's Hospital

🇨🇳

Beijing, Beijing, China

Beijing Tiantan Hospital Affiliated to Capital Medical University

🇨🇳

Beijing, Beijing, China

Guangdong Provincial Hospital of Chinese Medicine

🇨🇳

Guangzhou, Guangdong, China

The First Affiliated Hospital, Sun Yat-sen University

🇨🇳

Guangzhou, Guangdong, China

The Third Affiliated Hospital of Guangzhou Medical University

🇨🇳

Guangzhou, Guangdong, China

Nanfang Hospital of Southern Medical University

🇨🇳

Guangzhou, Guangdong, China

The First Affiliated Hospital of Guangzhou Medical University

🇨🇳

Guangzhou, Guangdong, China

Shenzhen Second People's Hospital

🇨🇳

Shenzhen, Guangdong, China

Hainan General Hospital

🇨🇳

Haikou, Hainan, China

Liuzhou Worker's Hospital - Fourth Affiliated Hospital of Guangxi Medical University

🇨🇳

Liuzhou, Guangxi, China

Affiliated Hospital of Zunyi Medical College

🇨🇳

Zunyi, Guizhou, China

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology

🇨🇳

Wuhan, Hubei, China

Peking University First Hospital

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath